Moderna’s booster shots against Covid19 have shown robust antibody responses, according to results of Phase 2 clinical trials published on Thursday. In the trial, Moderna tested a 50-microgram dose of three vaccine booster candidates in previously vaccinated individuals. The findings discovered that it induced robust antibody responses against the wild type D614G Covid-19 strain and against important variants of concern including Gamma (P1); Beta (B1351); and Delta (B16172), the US pharmaceutical major said in a statement. “Neutralising antibody levels following the boost approached those observed after primary vaccination with two doses of 100 microgram of mRNA-1273,” it added.
The Moderna’s added that its Covid-19 vaccine does not wane away and remains durable through six months after the second dose. The result of its clinical trial, which started in late July 2020 and recruited about 30,000 volunteers, showing 94.1 percent efficacy did not change much after six months, the company said in a statement. The data has been submitted to a peer-reviewed journal for publication. Moderna has also filed to the US FDA for final approval of its vaccine on June 1 and expects to complete its submission in August.
Scientists identify protein in the blood could be responsible for inflammatory response
Antimicrobial resistance can usher a pandemic worse than Covid-19: Study
Sero survey report by ICMR shows Rajasthan has 2nd highest Covid antibodies after MP